Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma-Reference-Cited by-全球学者库

登录注册会员服务联系我们

Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma

Published:2020 Issue:5 Volume:8 Page:895-907
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Song Lina¹²³⁴⁵,Chen Yi⁶⁷⁸⁹¹⁰,Ding Jiali¹¹¹²⁹¹³⁵,Wu Haoan⁶⁷⁸⁹¹⁰,Zhang Wei¹⁴¹⁵¹³⁵,Ma Ming⁶⁷⁸⁹¹⁰,Zang Fengchao¹⁶⁹¹³⁵,Wang Zhongqiu¹²³⁴⁵,Gu Ning⁶⁷⁸⁹¹⁰^ORCID,Zhang Yu⁶⁷⁸⁹¹⁰^ORCID

Affiliation:

1. Department of Radiology

2. Jiangsu Province Hospital of Chinese Medicine

3. Affiliated Hospital of Nanjing University of Chinese Medicine

4. Nanjing 210029

5. P. R. China

6. State Key Laboratory of Bioelectronics

7. Jiangsu Key Laboratory for Biomaterials and Devices

8. School of Biological Science and Medical Engineering & Collaborative Innovation Centre of Suzhou Nano Science and Technology

9. Southeast University

10. Nanjing 210096

11. Informatics Center

12. Zhongda Hospital

13. Nanjing 210009

14. The Jiangsu Province Research Institute for Clinical Medicine

15. the First Affiliated Hospital with Nanjing Medical University

16. Jiangsu Key Laboratory of Molecular and Functional Imaging, Medical School

Abstract

The Fe₃O₄-PEG-nAb multivalent nanoprobes provide a possible avenue to improve the cancer therapy of rituximab towards clinical application.

Funder

National Natural Science Foundation of China

National Basic Research Program of China

Fundamental Research Funds for the Central Universities

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering,General Chemistry,General Medicine

Link

http://pubs.rsc.org/en/content/articlepdf/2020/TB/C9TB02521A

Reference51 articles.

1. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections

2. From the bench to the bedside: ways to improve rituximab efficacy

3. Rituximab resistance

4. Antigenic Modulation and Rituximab Resistance

5. Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent trends in preparation and biomedical applications of iron oxide nanoparticles;Journal of Nanobiotechnology;2024-01-08

2. A miRNA-based gene therapy nanodrug synergistically enhances pro-inflammatory antitumor immunity against melanoma;Acta Biomaterialia;2023-01

3. Identifying nanocarrier–target interaction;Nanotechnology Principles in Drug Targeting and Diagnosis;2023

4. Immuno-PET Imaging and Radioimmunotherapy of Lymphomas;Molecular Pharmaceutics;2022-09-01

5. Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties;Molecules;2022-08-25

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前全球学者库共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3